BridgeBio Pharma Inc Total Liabilities
BridgeBio Pharma Inc total liabilities. Based on the latest financial reports, BridgeBio Pharma Inc (BBIO) has total liabilities worth $3.72 Billion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check BBIO financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of BridgeBio Pharma Inc (2017–2025)
Total liabilities of BridgeBio Pharma Inc from 2017 to 2025. This chart illustrates how BridgeBio Pharma Inc's total liabilities have evolved over time, based on quarterly financial data. Explore BridgeBio Pharma Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
BridgeBio Pharma Inc Competitors by Total Liabilities
The table below lists competitors of BridgeBio Pharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai Rural Commercial Bank Co Ltd
SHG:601825
|
China | CN¥1.51 Trillion |
|
Lifco AB (publ)
ST:LIFCO-B
|
Sweden | Skr23.20 Billion |
|
COLOPLAST SP.ADR 1/10 DK1
F:CBH
|
Germany | €34.99 Billion |
|
Yunnan Aluminium Co Ltd
SHE:000807
|
China | CN¥11.08 Billion |
|
GRAB HOLDINGS LTD CL.A
F:A6I
|
Germany | €5.23 Billion |
|
Taiwan Mobile Co Ltd
TW:3045
|
Taiwan | NT$145.33 Billion |
|
Guardant Health Inc
NASDAQ:GH
|
USA | $2.10 Billion |
|
Wolters Kluwer N.V.
AS:WKL
|
Netherlands | €8.79 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down BridgeBio Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see BridgeBio Pharma Inc assets under control.
Liquidity & Leverage Metrics
BridgeBio Pharma Inc Total Liabilities Ratios Explained
BridgeBio Pharma Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.23 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.48 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BridgeBio Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BridgeBio Pharma Inc (2017–2025)
The table below shows the annual total liabilities of BridgeBio Pharma Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.01 Billion | +26.74% |
| 2024-12-31 | $2.38 Billion | +25.84% |
| 2023-12-31 | $1.89 Billion | +1.12% |
| 2022-12-31 | $1.87 Billion | -0.55% |
| 2021-12-31 | $1.88 Billion | +215.32% |
| 2020-12-31 | $595.70 Million | +282.59% |
| 2019-12-31 | $155.70 Million | -72.51% |
| 2018-12-31 | $566.44 Million | +270.88% |
| 2017-12-31 | $152.73 Million | -- |
About BridgeBio Pharma Inc
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopteri… Read more